Daniela Catanzaro

Verified @gmail.com

LTCA-ULSS8

Daniela Catanzaro


            Download Compact PDF  
https://researchid.co/d.catanzaro
22

Scopus Publications

Scopus Publications

  • Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial
    Roberto Tonelli, Francesca Pischiutta, Francesca Elice, Elisa R Zanier, Giulia Grisendi, Giuseppe Astori, Anna Valeria Samarelli, Giulia Bruzzi, Linda Manicardi, Carlotta Spano, Giovanni Nattino, Fabiola Signorini, Martina Bernardi, Daniela Catanzaro, Anna Merlo, Ilaria Lisi, Laura Pasetto, Valentina Bonetto, Laura Fiammenghi, Laura Boschi, Simona Guidi, Olivia Candini, Tommaso Zoerle, Erica Dander, Giovanna D’Amico, Ferruccio De Pierri, Michela Maur, Elisa Pettorelli, Valentina Ruggieri, Stefania Cerri, Giorgio Mari, Giorgia De Berardis, Pasquale Mighali, Maria Cristina Baschieri, Lorenza Lazzari, Franco Bambi, Rachele Ciccocioppo, Enrico Clini, Massimo Dominici
    Cytotherapy, 2025
    BACKGROUND AIMS: SARS-CoV-2 infection triggers respiratory inflammation with potentially fatal systemic effects. Mesenchymal stromal/stem cells (MSCs) are promising for treating severe COVID-19 due to their anti-inflammatory and regenerative capacities. This study investigates the effects of allogeneic MSCs in severe COVID-19 pneumonia. METHODS: In the phase I/IIa RESCAT trial (May 2021-Feb 2022), patients with severe COVID-19 pneumonia received two intravenous MSC infusions and were compared to a control group (CTRL). To assess cytokine and biomarker responses, the MSC group was matched 1:2 with standard care patients (mCTRL) by age, gender, BMI, and PaO2/FiO2 (Nov 2020-Feb 2021). Random-effects linear regression evaluated cytokine and biomarker trends over time between MSC and control groups. RESULTS: Seventeen patients (MSC = 5, CTRL = 2, mCTRL = 10) were analyzed. Two MSC infusions were feasible and safe, with all patients discharged on average 15 ± 3.7 days postsecond infusion. While IL1RA and IL18 levels significantly increased in CTRL-mCTRL patients (P = 0.044 and P = 0.032), MSC treatment averted these rises, showing a distinct trajectory, particularly for IL1RA. MSC treatment also reduced IL6 levels compared to CTRL-mCTRL, while both groups showed similar reductions in Long pentraxin. Furthermore, MSC infusions prevented the neurofilament light chain surge observed in CTRL patients. CONCLUSIONS: MSC in COVID-19 patients resulted safe and feasible, effectively modulating inflammatory cytokines, in particular mitigating brain damage related biomarker, suggesting both reduced inflammation and a potential neurological protection.
  • A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report
    Francesca Elice, Roberta Sommaggio, Elisa Cappuzzello, Marcello Riva, Maria Chiara Tisi, Martina Bernardi, Angela Bozza, Daniela Catanzaro, Katia Chieregato, Anna Merlo, Ilaria Giaretta, Anna Dalla Pieta, Mauro Krampera, Carlo Visco, Livio Trentin, Andrea Visentin, Alberto Tosetto, Giuseppe Astori, Antonio Rosato
    Haematologica, 2024
    Not available.
  • Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9)
    Caterina Vianello, Veronica Cocetta, Daniela Catanzaro, Gerald W Dorn, Angelo De Milito, Flavio Rizzolio, Vincenzo Canzonieri, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli, Vincenzo Quagliariello, Annabella Di Mauro, Simona Losito, Nicola Maurea, Cono Scaffa, Gabriele Sales, Luca Scorrano, Marta Giacomello, Monica Montopoli
    Cell Death and Disease, 2024
    Authors and Affiliations Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo E. Meneghetti 2, 35131, Padova, Italy Caterina Vianello, Veronica Cocetta, Daniela Catanzaro & Monica Montopoli Department of Biology, University of Padova, Via Ugo Bassi 58B, 35131, Padova, Italy Caterina Vianello, Gabriele Sales, Luca Scorrano & Marta Giacomello Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO, 63110, USA Gerald W Dorn II Sprint Bioscience, Huddinge, Sweden Angelo De Milito Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden Angelo De Milito Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, 30172, Venice, Italy Flavio Rizzolio Pathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS, 33081, Aviano, Italy Flavio Rizzolio & Vincenzo Canzonieri Department of Medical, Surgical and Health Sciences, University of Trieste, 34149, Trieste, Italy Vincenzo Canzonieri Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081, Aviano, Italy Erika Cecchin, Rossana Roncato & Giuseppe Toffoli Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy Vincenzo Quagliariello & Nicola Maurea Pathology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy Annabella Di Mauro & Simona Losito Gynecologic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy Cono Scaffa Veneto Institute of Molecular Medicine, Via Orus 2, 35129, Padova, Italy Luca Scorrano & Monica Montopoli Department of Biomedical Sciences, Via Ugo Bassi 58B, 35131, Padova, Italy Marta Giacomello Authors Caterina Vianello View author publications You can also search for this author in PubMed Google Scholar Veronica Cocetta View author publications You can also search for this author in PubMed Google Scholar Daniela Catanzaro View author publications You can also search for this author in PubMed Google Scholar Gerald W Dorn II View author publications You can also search for this author in PubMed Google Scholar Angelo De Milito View author publications You can also search for this author in PubMed Google Scholar Flavio Rizzolio View author publications You can also search for this author in PubMed Google Scholar Vincenzo Canzonieri View author publications You can also search for this author in PubMed Google Scholar Erika Cecchin View author publications You can also search for this author in PubMed Google Scholar Rossana Roncato View author publications You can also search for this author in PubMed Google Scholar Giuseppe Toffoli View author publications You can also search for this author in PubMed Google Scholar Vincenzo Quagliariello View author publications You can also search for this author in PubMed Google Scholar Annabella Di Mauro View author publications You can also search for this author in PubMed Google Scholar Simona Losito View author publications You can also search for this author in PubMed Google Scholar Nicola Maurea View author publications You can also search for this author in PubMed Google Scholar Cono Scaffa View author publications You can also search for this author in PubMed Google Scholar Gabriele Sales View author publications You can also search for this author in PubMed Google Scholar Luca Scorrano View author publications You can also search for this author in PubMed Google Scholar Marta Giacomello View author publications You can also search for this author in PubMed Google Scholar Monica Montopoli View author publications You can also search for this author in PubMed Google Scholar Corresponding authors Correspondence to Marta Giacomello or Monica Montopoli .
  • Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9)
    Caterina Vianello, Veronica Cocetta, Daniela Catanzaro, Gerald W Dorn, Angelo De Milito, Flavio Rizzolio, Vincenzo Canzonieri, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli, Vincenzo Quagliariello, Annabella Di Mauro, Simona Losito, Nicola Maurea, Cono Scaffa, Gabriele Sales, Luca Scorrano, Marta Giacomello, Monica Montopoli
    Cell Death and Disease, 2023
    Authors and Affiliations Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo E. Meneghetti 2, 35131, Padova, Italy Caterina Vianello, Veronica Cocetta, Daniela Catanzaro & Monica Montopoli Department of Biology, University of Padova, Via Ugo Bassi 58B, 35131, Padova, Italy Caterina Vianello, Gabriele Sales, Luca Scorrano & Marta Giacomello Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO, 63110, USA Gerald W Dorn II Sprint Bioscience, Huddinge, Sweden Angelo De Milito Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden Angelo De Milito Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, 30172, Venice, Italy Flavio Rizzolio Pathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS, 33081, Aviano, Italy Flavio Rizzolio & Vincenzo Canzonieri Department of Medical, Surgical and Health Sciences, University of Trieste, 34149, Trieste, Italy Vincenzo Canzonieri Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081, Aviano, Italy Erika Cecchin, Rossana Roncato & Giuseppe Toffoli Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy Vincenzo Quagliariello & Nicola Maurea Pathology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy Annabella Di Mauro & Simona Losito Gynecologic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy Cono Scaffa Veneto Institute of Molecular Medicine, Via Orus 2, 35129, Padova, Italy Luca Scorrano & Monica Montopoli Department of Biomedical Sciences, Via Ugo Bassi 58B, 35131, Padova, Italy Marta Giacomello Authors Caterina Vianello View author publications You can also search for this author in PubMed Google Scholar Veronica Cocetta View author publications You can also search for this author in PubMed Google Scholar Daniela Catanzaro View author publications You can also search for this author in PubMed Google Scholar Gerald W Dorn II View author publications You can also search for this author in PubMed Google Scholar Angelo De Milito View author publications You can also search for this author in PubMed Google Scholar Flavio Rizzolio View author publications You can also search for this author in PubMed Google Scholar Vincenzo Canzonieri View author publications You can also search for this author in PubMed Google Scholar Erika Cecchin View author publications You can also search for this author in PubMed Google Scholar Rossana Roncato View author publications You can also search for this author in PubMed Google Scholar Giuseppe Toffoli View author publications You can also search for this author in PubMed Google Scholar Vincenzo Quagliariello View author publications You can also search for this author in PubMed Google Scholar Annabella Di Mauro View author publications You can also search for this author in PubMed Google Scholar Simona Losito View author publications You can also search for this author in PubMed Google Scholar Nicola Maurea View author publications You can also search for this author in PubMed Google Scholar Cono Scaffa View author publications You can also search for this author in PubMed Google Scholar Gabriele Sales View author publications You can also search for this author in PubMed Google Scholar Luca Scorrano View author publications You can also search for this author in PubMed Google Scholar Marta Giacomello View author publications You can also search for this author in PubMed Google Scholar Monica Montopoli View author publications You can also search for this author in PubMed Google Scholar Corresponding authors Correspondence to Marta Giacomello or Monica Montopoli .
  • Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera
    Angela Bozza, Martina Bernardi, Daniela Catanzaro, Katia Chieregato, Anna Merlo, Giuseppe Astori
    Hematology United Kingdom, 2023
    OBJECTIVE Polycythemia Vera (PV) is a myeloproliferative neoplasm characterized by the overproduction of red blood cells. First-line therapies are directed at lowering hematocrit levels. After the discovery of a mutation in the Janus kinase 2 (JAK2V617F), JAK2 inhibitors have been tested as second-line therapies. Despite these approaches, there is still the need for a major comprehension of the mechanisms involved in PV erythrocytosis and of more effective therapies. Angiotensin-converting enzyme (ACE) stimulates hematopoietic precursors proliferation and erythroid differentiation. We thus hypothesized that ACE inhibition could help in controlling erythrocytosis in PV. METHODS We assessed the clonogenic potential by colony-forming unit (CFU) assay of mononuclear cells isolated from PV JAK2 positive or JAK2 negative patients with erythrocytosis treated with enalaprilat or losartan. RESULTS Treatment with drugs led to a decrease of erythroid precursor frequency both in the presence and absence of JAK2 mutation, with a high extent in JAK2 positive cells and without affecting other types of precursors. No dose-dependent effect was observed. CONCLUSIONS Our results demonstrate that ACE inhibition reduces erythroid precursor frequency, confirming the involvement of ACE in erythrocytosis despite the presence of JAK2 mutation and encouraging the hypothesis that ACE inhibitors and AT1R antagonists could help in directly managing erythrocytosis in PV.
  • Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9)
    Caterina Vianello, Veronica Cocetta, Daniela Catanzaro, Gerald W Dorn, Angelo De Milito, Flavio Rizzolio, Vincenzo Canzonieri, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli, Vincenzo Quagliariello, Annabella Di Mauro, Simona Losito, Nicola Maurea, Scaffa Cono, Gabriele Sales, Luca Scorrano, Marta Giacomello, Monica Montopoli
    Cell Death and Disease, 2022
  • Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
    Caterina Vianello, Veronica Cocetta, Daniela Catanzaro, Gerald W Dorn, Angelo De Milito, Flavio Rizzolio, Vincenzo Canzonieri, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli, Vincenzo Quagliariello, Annabella Di Mauro, Simona Losito, Nicola Maurea, Scaffa Cono, Gabriele Sales, Luca Scorrano, Marta Giacomello, Monica Montopoli
    Cell Death and Disease, 2022
    Cisplatin (CDDP) is commonly used to treat a multitude of tumors including sarcomas, ovarian and cervical cancers. Despite recent investigations allowed to improve chemotherapy effectiveness, the molecular mechanisms underlying the development of CDDP resistance remain a major goal in cancer research. Here, we show that mitochondrial morphology and autophagy are altered in different CDDP resistant cancer cell lines. In CDDP resistant osteosarcoma and ovarian carcinoma, mitochondria are fragmented and closely juxtaposed to the endoplasmic reticulum; rates of mitophagy are also increased. Specifically, levels of the mitophagy receptor BNIP3 are higher both in resistant cells and in ovarian cancer patient samples resistant to platinum-based treatments. Genetic BNIP3 silencing or pharmacological inhibition of autophagosome formation re-sensitizes these cells to CDDP. Our study identifies inhibition of BNIP3-driven mitophagy as a potential therapeutic strategy to counteract CDDP resistance in ovarian carcinoma and osteosarcoma.
  • Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide
    Daniela Catanzaro, Gloria Milani, Angela Bozza, Martina Bernardi, Katia Chieregato, Martina Menarin, Anna Merlo, Paola Celli, Romina Belli, Daniele Peroni, Alessandro Pozzato, Gianantonio Pozzato, Fabio Angelo Raneri, Lorenzo Volpin, Marco Ruggeri, Giuseppe Astori
    British Journal of Cancer, 2022
    Background Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness. Despite advances in surgery and radio-chemotherapy, patients continue to have poor prognoses, with a survival rate of 14–15 months. Thus, new therapeutic strategies are needed. Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies. Methods Here, the anticancer activity of quantum molecular resonance (QMR) was investigated. For this purpose, three glioblastoma cell lines were tested, and the QMR effect was evaluated on cancer cell proliferation rate and aggressiveness. To clarify the QMR mechanism of action, the proteomic asset after stimulation was delineated. Mesenchymal stromal cells and astrocytes were used as healthy controls. Results QMR affected cancer cell proliferation, inducing a significant arrest of cell cycle progression and reducing cancer tumorigenicity. These parameters were not altered in healthy control cells. Proteomic analysis suggested that QMR acts not only on DNA replication but also on the machinery involved in the mitotic spindle assembly and chromosome segregation. Moreover, in a combined therapy assessment, QMR significantly enhanced temozolomide efficacy. Conclusions QMR technology appears to be a promising tool for glioblastoma treatment.
  • Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress
    Veronica Cocetta, Paolo Governa, Vittoria Borgonetti, Mattia Tinazzi, Gregorio Peron, Daniela Catanzaro, Massimiliano Berretta, Marco Biagi, Fabrizio Manetti, Stefano Dall’Acqua, Monica Montopoli
    Frontiers in Pharmacology, 2021
    The relevance and incidence of intestinal bowel diseases (IBD) have been increasing over the last 50 years and the current therapies are characterized by severe side effects, making essential the development of new strategies that combine efficacy and safety in the management of human IBD. Herbal products are highly considered in research aimed at discovering new approaches for IBD therapy and, among others, Cannabis sativa L. has been traditionally used for centuries as an analgesic and anti-inflammatory remedy also in different gastrointestinal disorders. This study aims to investigate the effects of different C. sativa isolated compounds in an in vitro model of intestinal epithelium. The ability of treatments to modulate markers of intestinal dysfunctions was tested on Caco-2 intestinal cell monolayers. Our results, obtained by evaluation of ROS production, TEER and paracellular permeability measurements and tight junctions evaluation show Cannabidiol as the most promising compound against intestinal inflammatory condition. Cannabidiol is able to inhibit ROS production and restore epithelial permeability during inflammatory and oxidative stress conditions, suggesting its possible application as adjuvant in IBD management.
  • Further assessment of Salvia haenkei as an innovative strategy to counteract skin photo-aging and restore the barrier integrity
    Veronica Cocetta, Jessica Cadau, Miriam Saponaro, Isabella Giacomini, Stefano Dall’Acqua, Stefania Sut, Daniela Catanzaro, Genny Orso, Giorgia Miolo, Luca Menilli, Andrea Pagetta, Eugenio Ragazzi, Monica Montopoli
    Aging, 2021
    Skin is the essential barrier of the human body which performs multiple functions. Endogenous factors, in concert with external assaults, continuously affect skin integrity, leading to distinct structural changes that influence not only the skin appearance but also its various physiological functions. Alterations of the barrier functions lead to an increased risk of developing disease and side reactions, thus the importance of maintaining the integrity of the epidermal barrier and slowing down the skin aging process is evident. Salvia haenkei (SH) has been recently identified as a potential anti-senescence agent; its extract is able to decrease the level of senescent cells by affecting the IL1α release and reducing reactive oxygen species (ROS) generation. In this study, SH extract was tested on human keratinocyte cell line (HaCaT) exposed to stress factors related to premature aging of cells such as free radicals and ultraviolet B radiation. We confirmed that SH acts as scavenger of ROS and found its ability to restore the skin barrier integrity by reinforcing the cytoskeleton structure, sealing the tight junctions and increasing the migration rate of cells. Given these results, this work becomes relevant, identifying Salvia haenkei as a compound useful for anti-aging skin treatment in clinical performance.
  • Logistics of an advanced therapy medicinal product during COVID-19 pandemic in Italy: successful delivery of mesenchymal stromal cells in dry ice
    Giuseppe Astori, Martina Bernardi, Angela Bozza, Daniela Catanzaro, Katia Chieregato, Anna Merlo, Monica Santimaria, Roberto Barbazza, Giuseppe Amodeo, Rachele Ciccocioppo, Francesca Elice, Marco Ruggeri
    Journal of Translational Medicine, 2020
  • A fixed combination of probiotics and herbal extracts attenuates intestinal barrier dysfunction from inflammatory stress in an in vitro model using caco-2 cells
    Veronica Cocetta, Daniela Catanzaro, Vittoria Borgonetti, Eugenio Ragazzi, Maria C. Giron, Paolo Governa, Ilaria Carnevali, Marco Biagi, Monica Montopoli
    Recent Patents on Food Nutrition and Agriculture, 2019
  • Effects of boswellia serrata roxb. And curcuma longa l. in an in vitro intestinal inflammation model using immune cells and caco-2
    Paolo Governa, Maddalena Marchi, Veronica Cocetta, Bianca De Leo, Philippa Saunders, Daniela Catanzaro, Elisabetta Miraldi, Monica Montopoli, Marco Biagi
    Pharmaceuticals, 2018
  • Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells
    Daniela Catanzaro, Silvia Nicolosi, Veronica Cocetta, Marika Salvalaio, Andrea Pagetta, Eugenio Ragazzi, Monica Montopoli, Gianfranco Pasut
    Oncotarget, 2018
  • Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression
    Daniela Catanzaro, Daniela Gabbia, Veronica Cocetta, Marco Biagi, Eugenio Ragazzi, Monica Montopoli, Maria Carrara
    Fitoterapia, 2018
  • Chlorogenic acid interaction with cisplatin and oxaliplatin: Studies in cervical carcinoma cells
    Daniela Catanzaro, Raffaella Filippini, Caterina Vianello, Maria Carrara, Eugenio Ragazzi, Monica Montopoli
    Natural Product Communications, 2016
  • Protective effects of ψ taraxasterol 3-O-myristate and arnidiol 3-O-myristate isolated from Calendula officinalis on epithelial intestinal barrier
    Stefano Dall'Acqua, Daniela Catanzaro, Veronica Cocetta, Nadine Igl, Eugenio Ragazzi, Maria Cecilia Giron, Laura Cecconello, Monica Montopoli
    Fitoterapia, 2016
  • Effect of quercetin on cell cycle and cyclin expression in ovarian carcinoma and osteosarcoma cell lines
    Daniela Catanzaro, Eugenio Ragazzi, Caterina Vianello, Laura Caparrotta, Monica Montopoli
    Natural Product Communications, 2015
  • Boswellia serrata preserves intestinal epithelial barrier from oxidative and inflammatory damage
    Daniela Catanzaro, Serena Rancan, Genny Orso, Stefano Dall’Acqua, Paola Brun, Maria Cecilia Giron, Maria Carrara, Ignazio Castagliuolo, Eugenio Ragazzi, Laura Caparrotta, Monica Montopoli
    Plos One, 2015
  • Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death
    Daniela Catanzaro, Edoardo Gaude, Genny Orso, Carla Giordano, Giulia Guzzo, Andrea Rasola, Eugenio Ragazzi, Laura Caparrotta, Christian Frezza, Monica Montopoli
    Oncotarget, 2015
  • Cell cycle control by natural phenols in cisplatin-resistant cell lines
    Daniela Catanzaro, Caterina Vianello, Eugenio Ragazzi, Laura Caparrotta, Monica Montopoli
    Natural Product Communications, 2014
  • Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA Ile mutation causing hypertrophic cardiomyopathy
    Elena Perli, Carla Giordano, Helen A.L. Tuppen, Monica Montopoli, Arianna Montanari, Maurizia Orlandi, Annalinda Pisano, Daniela Catanzaro, Laura Caparrotta, Beatrice Musumeci, Camillo Autore, Veronica Morea, Patrizio Di Micco, Antonio F. Campese, Martina Leopizzi, Pietro Gallo, Silvia Francisci, Laura Frontali, Robert W. Taylor, Giulia d'Amati
    Human Molecular Genetics, 2012